Key result
In patients with obesity-related hypertension, systolic blood pressure response to aliskiren was significantly greater in those with a BMI > 30.7 kg/m2 (-21 mmHg) compared to those ≤ 30.7 kg/m2 (-4 mmHg).
Why the study?
Do patient characteristics modify the blood pressure-lowering response to aliskiren, moxonidine, and hydrochlorothiazide in patients with obesity-related hypertension?
RCT (n=31)
Double-blind
Random order
No
Do patient characteristics modify the blood pressure-lowering response to aliskiren, moxonidine, and hydrochlorothiazide in patients with obesity-related hypertension?
In patients with obesity-related hypertension, baseline characteristics such as BMI, hsCRP, heart rate, and renin levels can help predict the magnitude of blood pressure reduction in response to specific antihypertensive drug classes.
Answers are grounded in this paper and cite their sources.
BMI may modify aliskiren response in obesity hypertension; hypothesis-generating and should not change practice.
BACKGROUND: In patients with obesity-related hypertension (ORH), reaction to antihypertensive medication is likely influenced by patientcharacteristics. METHODS: Effects of aliskiren, moxonidine and hydrochlorothiazide on 24-h blood pressure (BP) were compared to placebo. Linear mixed effect models were used to analyze the effect of patient characteristics on BP levels and treatment response. RESULTS: Systolic BP response to aliskiren was higher in patients with a BMI > 30.7 kg/m2 compared to patients with a BMI ≤ 30.7 kg/m2 (-21 mmHg versus -4 mmHg). In patients with a hsCRP > 1.8 mg/L the systolic BP response to aliskiren was higher than in patients with a low hsCRP (-15 mmHg versus -7 mmHg). Hydrochlorothiazide (HCTZ) treatment effect on systolic BP was -13 mmHg when heart rate > 71 beats/min compared to -3 mmHg when heart rate was ≤ 71 beats/min. CONCLUSION: In patients with ORH, BP response to aliskiren is positively related to BMI and hsCRP. Systolic BP response to HCTZ is positively related to heart rate and negatively to renin levels. TRIAL REGISTRATION: NCT01138423. Registered June 4th, 2010.
No takes yet. Share an insight, caveat, or question.
Schrover et al. (2017) conducted an RCT in Obesity-related hypertension (n=31). Aliskiren, moxonidine, hydrochlorothiazide vs. Placebo was evaluated on Change in 24-h systolic blood pressure response to aliskiren in patients with BMI > 30.7 kg/m2 vs ≤ 30.7 kg/m2 (p=0.01 for interaction). In patients with obesity-related hypertension, systolic blood pressure response to aliskiren was significantly greater in those with a BMI > 30.7 kg/m2 (-21 mmHg) compared to those ≤ 30.7 kg/m2 (-4 mmHg).
Synapse has enriched 10 related papers. Consider them for comparative context: